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Introduction. Viral hepatitis C (HCV) is a significant global health problem. The risk of de-
veloping chronic HCV is up to 80% of patients, of whom 10-20% can develop liver cirrhosis 
or hepatocellular carcinoma which can lead to death. Treatment with direct-acting antivi-
ral agents (DAAs) contributes to a sustained virological response (SVR) in 97-99% of cases.
Material and methods. The study was conducted on 206 patients with chronic HCV who 
underwent two generic antiviral agent therapies: group I (103) – Sofosbuvir 400 mg + Ledi-
pasvir 80 mg, whereas group II (103) – Sofosbuvir 400 mg + Daclatasvir 60 mg orally, once 
a day, for 12 weeks. The assessment of hepatitis C virus RNA and genotype, as well as the 
degree of hepatic fibrosis by Fibroscan, biochemical and complete blood count (CBC) indices 
were carried out.
Results. The study results showed high efficacy of the generic DAAs treatment in patients 
with chronic HCV over 12 weeks. The SVR rate made up 90.3% in Sofosbuvir + Ledipasvir 
therapy and 86.4% – in Sofosbuvir + Daclatasvir. Similar treatment response was record-
ed in naive patients and those who previously underwent unsuccessful treatment with Pe-
gylated Interferon and Ribavirin. The DAAs treatment showed the following minor adverse 
reactions: asthenia, headache, sleep disorder, and nausea, which did not require treatment 
discontinuation.
Conclusions. The 12-week course of DAAs therapy exhibited high SVR rate in both chronic 
HCV naive patients and those previously treated with Pegylated Interferon and Ribavirin.
Cuvinte cheie: HVC 
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EFICACITATEA TRATAMENTULUI CU PREPARATE ANTIVIRALE CU ACȚIUNE DIRECTĂ 
LA PACIENȚII CU HEPATITĂ VIRALĂ C CRONICĂ
Introducere. Hepatita virală C (HVC) este o maladie cu un impact semnificativ la nivel 
mondial. Riscul de cronicizare a HVC este de până la 80% dintre pacienții diagnosticați cu 
această maladie iar 10-20% dintre aceștea dezvoltă ciroza hepatică, carcinomul hepatoce-
lular sau poate surveni decesul. Tratamentul cu preparatele antivirale, cu acțiune directă 
(PAAD) contribuie la obținerea răspunsului virusologic susținut (RVS) în 97-99% de cazuri 
morbide.
Material și metode. Studiul științific a inclus 206 de pacienţi cu HVC cronică, care au primit 
două scheme de preparate antivirale generice: I lot (103) – Sofosbuvir, 400 mg + Ledipasvir, 
80 mg, însă cei din lotul II (103) – Sofosbuvir, 400 mg + Daclatasvir, 60 mg per os, o dată în 
zi, timp de 12 săptămâni. Au fost evaluate ARN-VHC, genotipul virusului C, gradul de fibroză 
hepatică prin Fibroscan, indicii biochimici și hemoleucograma.
Rezultate. Rezultatele studiului au demonstrat randamentul ridicat al tratamentului cu 
PAAD, efectuat pe parcursul a 12 săptămâni pacienților cu HVC cronică. Rata RVS a fost de 
90,3% – în cazul tratamentului cu Sofosbuvir + Ledipasvir și 86,4% – cu Sofosbuvir + Da-
clatasvir. Răspunsul la tratament a fost similar la pacienții naivi și la cei tratați anterior cu 
Interferon pegilat și Ribavirină – fără succes. Tratamentul antiviral cu PAAD a î�nregistrat 
react�ii adverse minore: astenie, cefalee, dereglarea somnului, grețuri, care nu au pretins 
întreruperea tratamentului.
Concluzii. Tratamentul cu PAAD, administrat timp de 12 săptămâni, a atins RVS ridicat atât 
la pacienții cu HVC cronică naivi, cât și cei tratați anterior cu PEG-INF și Ribavirină.
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INTRODUCTION
Viral hepatitis C is a significant global health pro-blem. According to the World Health Organization data, 71 million people with hepatitis C virus are estimated worldwide, accounting for 1.2% of the world population. Approximately 399 000 peo-ple die annually from HCV-related complications, which include cirrhosis, hepatocellular carcinoma and liver failure (1). Annually, 3-4 million new cases of HCV occur, including 1300-1400 cases in the Republic of Moldova. The prevalence of HCV infection considerably ranges from a very low le-vel (0.05-0.1%) in the UK and Scandinavian coun-
tries, to the highest level in Asia and Egypt (˃5-10%) (2, 3). The HCV incidence in the Republic of Moldova was estimated at 4.5-5.0% in the overall population with the prevalence of genotype 1b, accounting for 98% (4, 5). People aged betwe-en 30-49 are predominantly affected, men being more common than women. The risk of chronic HCV infection is very high. Untreated acute hepati-tis C can develop into a chronic form in up to 80% of people, of whom 10-20% develop liver cirrhosis over 20 years, followed by decompensated liver disease, hepatocellular carcinoma and even death (6). Once the onset of chronic infection occurs, 
the rate of spontaneous recovery is significantly reduced. Chronic HCV in most patients develops 
asymptomatically or nonspecifically, as long as no cirrhosis is present (7, 8, 9). As a result, HVC is often diagnosed accidentally or remains undia-gnosed. It has been estimated that only 30-50% of HCV people are aware of their disease. Therefore, the lack of an effective vaccine, that would con-tribute to a decrease in HCV morbidity rate and subsequent consequences, requires the develop-ment of early diagnostic measures and treatment in order to eradicate the infection. Once HCV is 
identified, the assessment of the therapeutic suc-cess is possible by dosing the amount of RNA-HCV and the sustained virologic response. Over time, the SVR rate increased from 5-20% in interferon monotherapy, to 40-50% in combined IFN + Riba-virin treatment. Currently, the SVR rate accounts for 95-100% in cases treated with DAAs (10). The major advantage in the treatment of chronic HVC is the opportunity to administer DAAs – NS3/4A protease inhibitors, NS5B polymerases and NS5A replication complex.These drugs require oral short-term administrati-on, having a high SVR rate and minimal side effects. 
The purpose of antiviral treatment is to definitely 
eliminate the virus and get negative RNA-HCV at a 6-month interval after treatment completion by 
obtaining a SVR. The literature data confirm that over 99% of patients who have obtained a SVR re-main HCV-negative over 4-5 years after the treat-ment was discontinued, with no signs of hepatitis. The long-term SVR showed a 75% reduction of he-patocellular carcinoma cases, decompensated and compensated cirrhosis and death over the next 15 years (11). It has recently been shown that pati-ents with SVR have a similar quality-of-life status as the overall population (7), whereas those with compensated and decompensated cirrhosis do not require liver transplant (9, 12).
MATERIAL AND METHODS
The purpose of the research: to study the effective-ness of Interferon-free treatment in patients with chronic HCV infection.
The research objectives: to assess the efficacy of the DAAs therapy: Sofosbuvir + Ledipasvir and Sofosbuvir + Daclatasvir in patients with chronic HCV infection. To study the evolution of clinical, biochemical, virological and paraclinical indices in patients with chronic HCV infection both at the beginning and end of treatment, as well as over 24 weeks after treatment. To analyze the adverse re-actions and complications that can occur after the DAAs treatment.
The research hypothesis: the emergence of new therapeutic opportunities allows each patient di-agnosed with chronic HCV infection to receive an-tiviral treatment. DAAs have shown a higher effi-cacy and tolerability, as well as shorter treatment duration compared to interferon therapy. A com-bination of at least two of the three major classes 
of drugs results in SVR≥95% in just 8-12 weeks of treatment. Patients who were treated for HCV in-fection exhibited a better quality of life, as well as a reduced risk of developing liver cirrhosis, hepa-tocellular carcinoma and death related to liver and extrahepatic diseases.The study was conducted on 206 adult patients with chronic HCV who initiated DAAs treatment within the PHMI Toma Ciorba Clinical Hospital of Infectious Diseases during 2017-2018.The inclusion criteria were as follows: patients 
≥18 years of age, with chronic HCV confirmed by anti-HCV, anti-HCV IgM, RNA-HCV>25 IU/mL, 
with F0-F3 fibrosis of all genotypes, naive patients 
ONE HEALTH &
RISK MANAGEMENT
VOL. 1, ISSUE 1
0202 LIRPA   
6
or patients subjected to a previous unsuccessful antiviral treatment.The exclusion criteria were as follows: pregnant and nursing patients, HIV-HBV-HVD co-infection, 
liver cirrhosis, F4 fibrosis, hepatocellular carcino-ma or other malignancies.The patients included in the study were randomly divided into two groups of 103 patients each. The study groups were comparable in terms of age and 
gender. The degree of liver fibrosis was assessed 
via Fibroscan. Patients with F0, F1, F2 and F3 fi-brosis were selected. Chronic HCV patients were initially diagnosed by detecting anti-HCV via the 
immuno-enzymatic assay and confirmed by ARN-HCV testing. Serum levels of ARN-HCV were de-termined by real-time polymerase chain reaction (PCR) with a low detection limit <25 IU/mL. Prior to treatment initiation, the HCV genotype was as-sessed (1a, 1b, 2, 3 and 4). Anamnestic, epidemio-logical, clinical, biochemical, serological and mole-cular biology data were collected in all patients at the beginning, over 4 and 12 weeks of treatment, as well as over 24 weeks after the antiviral treat-ment completion.The 1st group included 103 patients treated with Twinvir (Sofosbuvir 400 mg/Ledipasvir 90 mg), (manufacturer: Incepta Pharmaceuticals, Bangla-desh), one pill orally, once daily, for 12 weeks.The 2nd group included 103 patients, undergo-ing treatment with Nucleobuvir (Sofosbuvir 400 mg) – one pill, and Daclavirdin (Daclatasvir 60 
mg) – one pill orally (manufacturer: EVʌPHʌRMA, Egypt), for 12 weeks.All patients signed an informed consent. The study protocol was positively endorsed by the Research Ethics Committee of Nicolae Testemitanu SUMPh (meeting no. 75 of 26.04.2017).
RESULTSOf the 206 patients with chronic HCV included in the study, there were 104 (50.5%) men and 102 (49.5%) women. There were patients aged betwe-en 20-79 years old, mean age 50.13±1.28 years. Patients aged 41-50 years – 55 (26.7%) were the most affected, as well as patients aged 51-60 years – 63 (30.6%). There were 19 (9.2%) patients aged 20-30, 33 (16%) patients aged 31-40 years, 30 (14.5%) patients aged 61-70 years, and 6 (2.9%) patients aged 71-80 years. More than half of the patients had concomitant digestive diseases or 
extrahepatic manifestations. The results were si-milar in both research groups. Most patients were naive, whereas 14 (13.6%) patients from group I and 11 (10.7%) patients from group II previously administered antivirals with Interferon, Ribavirin, Boceprevir or Telaprevir, but unsuccessfully. Of the total number of patients, 174 (84.4%) were infected with genotype 1. Of them, 170 cases were detected with 1b GT, 2 patients with GT 1a and mi-xed GT (1a+1b) each, 2 (1%) patients – genotype 2, 10 (4.9%) patients – genotype 3, of whom 6 – genotype 3a and 2 patients had mixed genotypes (3a+ 3b) and (3a+1b) each, one patient (0.5%) – genotype 4+1b. The only diagnostic tests available in the Republic of Moldova were for genotypes 1-4. Genotypes 5, 6 and 7 have remained uniden-
tified. Therefore, 19 (9.2%) patients with detecta-ble quantitative HCV RNA have not been assessed for genotype (tab. 1).FibroScan elastometry assessment or elastogra-
phy detected minor F0-F1 fibrosis in 70 (34%) pa-
tients, moderate fibrosis (F2) in 55 (26.7%) cases 
and advanced fibrosis (F3) in 81 (39.3%) cases. Patients of group I more frequently exhibited mi-
nor fibrosis – in 52 (50.5%) cases, and group II had 
predominantly advanced fibrosis in 58 (56.3%) cases. At the beginning of antiviral treatment, the level of HCV viremia ranged from 2 168 to 64 402 936 copies/mL (mean value – 6 413 266 ± 776 
462 copies/mL) and did not differ significantly in both groups (tab. 1).At least one gastrointestinal disease, such as chro-nic pancreatitis, chronic cholecystitis or chronic gastroduodenopathy was found in 64 (62.1%) patients from group I and in 60 (58.2%) patients from group II.Concomitant chronic hepatitis C virus infection with diabetes were found in 62 (30.1%) patients, with hypertensive disease – in 63 (30.6%), ische-mic heart disease – in 27 (13.1%), autoimmune thyroiditis – 18 (8.7%), and vasculitis – 20 (9.7%), which could be extrahepatic manifestations of HCV, due to unknown disease onset (tab. 2).Patients with extrahepatic manifestations were ol-der (55.86±0.97 years) than those without mani-festations (45.08±1.07 years) (p<0.001). Patients without extrahepatic manifestations exhibited a short-term disease from the time of detection (9.52±0.58 years), compared to those who had ex-trahepatic manifestations (11.54±
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0.63 years), (p<0.05). There were no contraindi-cations for DAAs, compared to Interferon treat-ment, in 9 (8.73%) patients from group I and in 6 (5.82%) patients from group II, who exhibited extrahepatic manifestations, as well as cancer re-mission. Table 1. General characteristics of chronic HCV patient groups at the initiation of antiviral treatment.
Indices Lot SOF+LDV(n=103)
Lot SOF+DCV
(n=103) OR 95% CI, P 
Age, years 50.03±1.29 50.24±1.28 >0.05
Males, n/(%)
Females, n/(%)
51 (49.5)52 (50.5) 53 (51.4)50 (48.6) 0.93 (0.54-1.60), >0.050.78 (0.63-1.87), >0.05
Gastrointestinal comorbidities, n/(%) 64 (62.1) 60 (58.2) 1.18 (0.67-2.06), >0.05
Extrahepatic manifestations, n/(%) 56 (54.3) 60 (58.21) 0.85 (0.49-1.48), >0.05
Previous antiviral treatment, n/(%) 14 (13.6) 11 (10.7) 1.32(0.57-3.05), >0.05
Genotype, n/(%)
1b
2
3 
4
Mixed
Unidentified 
98 (95.1)1 (0.97)0004 (3.88)
72 (69.9)1 (0.97)10 (9.7)1 (0.97)4 (3.88)15 (14.5)
8.43 (3.13-22.76), <0.001
0.24 (0.08-0.74), <0.05
Fibrosis staging, n/(%)
F0-F1
F2
F3
52 (50.5)28 (27.2)23 (22.3) 18 (17.5)27 (26.2)58 (56.3) 4.81 (2.54-9.12), <0.0011.05 (0.57-1.94), >0.050.22 (0.12-0.41), <0.001
ARN-VHC, copies /mL, mean value 6.231.148±745.259 6.595.385± 1.450.617 >0.05
Table 2. Comorbidities of patients with chronic HCV at the initiation of antiviral treatment.
Comorbidities Lot SOF+LDV(n=103)
Lot SOF+DCV
(n=103) OR 95% CI, P 
Chronic pancreatitis, n/(%) 23 (22.33) 26 (25.24) 1.17 (0.61-2.23), >0.05
Chronic cholecystitis, n/(%) 31 (30.09) 26 (25.24) 0.78 (0.42-1.44), >0.05
Chronic gastroduodenopathy, n/(%) 26 (25.24) 25 (24.27) 0.95 (0.50-1.78), >0.05
Diabetes mellitus, n/(%) 32 (31.06) 30 (29.12) 0.91 (0.50-1.65), >0.05
Hypertensive disease, n/(%) 22 (21.35) 41 (39.8) 2.43 (1.32-4.50), <0.01
Cardiomyopathy, n/(%) 17 (16.5) 10 (9.7) 0.54 (0.24-1.25), >0.05
Tumors, n/(%) 9 (8.73) 6 (5.82) 0.65 (0.22-1.88), >0.05
Obesity, n/(%) 11 (10.68) 13 (12.62) 1.21 (0.51-2.83), >0.05
Autoimmune thyroiditis, n/(%) 9 (8.73) 9 (8.73) 1.0 (0.38-2.63), >0.05
Vasculitis, n/(%) 9 (8.73) 11 (10.68) 1.25 (0.49-3.15), >0.05The DAAs treatment showed a good biochemical 
response even from the first month of treatment. 
There was a significant ALAT decrease in both groups, thus over 4 weeks of treatment, the mean ALAT values showed decreasing rate of 3.47 times in group I and 2.81 times in group II, which reached the normal indices and maintained during the tre-
atment and after its completion (p<0.001) (fig. 1).Virologic response over 12 weeks after the treatment was recorded in 95 (92.2%) patients treated with SOF+LDV; in 90 (87.4%) patients with SOF+DCV, 
RNA-HCV it was undetectable. Virologic failure at the end of treatment was recorded in 8 (7.8%) patients from group I and in 13 (12.6%) from group II.Over 24 weeks after antiviral treatment comple-tion, undetectable RNA-HCV was maintained in 93 (90.3%) patients in group I and 89 (86.4%) in group II. Although the SVR24 rate in patients who administered SOF+LDV treatment was higher than in those with SOF+DCV, there was not any statisti-
cally significant difference OR=0.68, 95% CI (0.20-
1.61), p=0.39 (fig. 2). 
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Table 3. Mean values of biochemical indices at the initiation of antiviral treatment.
Biochemical parameters Lot SOF+LDV(n=103)
Lot SOF+DCV
(n=103) PThymol test, U 4.78±0.28 6.0±0.31 <0.01Total bilirubin, µmol/L 16.54±0.93 15.98±0.73 >0.05ALAT, IU/L 108.23±12.2 118.8±14.78 >0.05ASAT, IU/L 81.8±8.44 90.38±7.49 >0.05Alkaline phosphatase, IU/L 206.17±9.18 183.94±8.68 >0.05GGT, UI/L 67.03±5.72 76.63±8.24 >0.05Glucose, mmol/L 5.96±0.18 6.05±0.19 >0.05Amylase, IU/L 89.44±4.83 99.14±5.25 >0.05Prothrombin time index, % 88.56±0.65 86.27±0.65 <0.05
Figure 1. Dynamics of ALAT activity in patients with chronic HCV treated with DAAs.
Figure 2. Virologic response in chronic Hepatitis C patients.* VR12 – virologic response at the end of treatment ** SVR24 – sustained virologic response over 24 weeks after treatment
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The analysis of the SVR-related predictive fac-tors in DAAs treatment (tab. 4, tab. 5), revealed that SVR was mostly found in patients with high cytolytic activity compared to those who had se-rum aminotransferase level within normal range. Young patients showed a more frequent SVR than those over 60, although the differences were not 
statistically significant. At the same time, patients 
with SVR showed a higher initial level of ALAT (117.75±10.69 IU/L), compared to those in whom virologic failure was recorded (79.68±11.88 IU/L), (p<0.05). The obtained data help to conclude that 
age, gender, level of viremia, liver fibrosis stage and genotype are not predictive factors of SVR in DAAs treatment.
Table 4. SVR-related predictive factors for Sofosbuvir+Ledipasvir treatment.
Factors SVR n=93 Total n=103 % 95% CI PAge
≤40 years 22 24 91.6 1.041-60 years 51 56 91.1 0.93 (0.17-5.15) 0.93
≥60 years 20 23 86.9 0.61 (0.09-4.01) 0.60GenderMales 48 51 94.1 1.0Females 45 52 86.5 0.40 (0.10-1.65) 0.21ALATNormal range 18 22 81.8 1.0> normal range 75 81 92.6 2.78 (0.71-10.89) 0.14ARN-VHC< 1 mln copies/mL 13 13 100 1.01-5 mln copies/mL 43 50 86.0 0.21 (0.01-4.01) 0.30>5 mln copies/ mL 37 40 92.5 0.40 (0.02-8.20) 0.55Fibrosis stage0-1 49 52 94.2 1.02-3 44 51 86.3 0.38 (0.09-1.58) 0.19Genotype1 88 98 89.8 1.02,3,4 1 1 100 0.36 (0.01-9.31) 0.53
Unidentified 4 4 100 1.06 (0.05-21.25) 0.97Table 5. SVR-related predictive factors for Sofosbuvir+Daclatasvir treatment.
Factors SVR n=89 Total n=103 % 95% CI PAge
≤40 years 24 27 88.9 1.041-60 years 47 53 88.7 0.98 (0.23-4.26) 0.98
≥60 years 18 23 78.3 0.45 (0.09-2.13) 0.31GenderMales 46 53 86.8 1.0Females 43 50 86 0.93 (0.30-2.88) 0.91ALATNormal range 14 18 77.8 1.0 > normal range 75 85 88.2 2.14 (0.59-7.8) 0.25ARN-VHC< 1 mln copies/mL 22 24 91.7 1.01-5 mln copies/mL 33 39 84.6 0.50 (0.09-2.70) 0.42>5 mln copies/ mL 34 40 85 0.52 (0.10-2.79) 0.44Fibrosis Stage0-1 15 18 83.3 1.02-3 74 85 87 1.35 (0.33-5.41) 0.68Genotype1 60 71 84.5 1,02, 3, 4 17 17 100 6.65 (0.37-118.64) 0.20
Unidentified 2 15 80 0.73 (0.17-3.03) 0.66
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Treatment failure was established in 24 (11.6%) patients. Of them, there were 14 women (58.3%) and 10 men (41.7%). There were 19 (79.2%) pati-ents over 40 years and those with an average (F2) 
and advanced (F3) fibrosis level 18 (75%) were more likely to fail the treatment. The ARN-HCV vi-remia level was similar in patients who had SVR and those with virologic failure. The SVR rate was similar in naive patients and those previously tre-
ated with antivirals, that was 160 (88.4%) and 22 (88%) cases, respectively. The DAAs therapy was well tolerated by patients from both groups, whereas 27 (13.1%) patients experienced minor adverse reactions like asthe-nia, headache, nausea, insomnia, hypertensive crisis, which were quickly compensated without suspending the treatment (tab. 6).
Table 6. Adverse reactions to antiviral treatment in patients with chronic HCV.
Indices
SOF/LDV SOF/DCV
OR 95% CI, PI II
N=103 N=103Asthenia, n (%) 4 (3.9) 5 (4.9) 0.79 (0.21-3.04), p= 0.73Headache, n (%) 4 (3.9) 3 (2.9) 1.35 (0.29-6.17), p= 0.70Nausea, n (%) 2 (1.9) 4 (3.9) 0.49 (0.09-2.73), p=0.42Insomnia, n (%) 3 (2.9) 2 (1.9) 1.51 (0.24-9.26), p=0.65Hypertensive seizures, n (%) 0 1 (0.97) 0.33 (0.01-8.20), p=0.50
DISCUSSIONSThe implementation of the National Program of combating viral hepatitis B, C and D over 2017 and 2021 has as an overall purpose to further reduce the morbidity rate of acute and chronic hepatitis B, C and D viral infections and cirrhosis, as well as minimize their socioeconomic consequences. Access to modern DAAs schemes leads to the disa-ppearance of HCV RNA over four weeks after tre-atment initiation, as well as to virus elimination in about 90% of cases. Reactivation of HCV over 24 weeks after DAAs treatment completion is rare, al-though reinfection should not be excluded. About 99% of patients who exhibited SVR had a negative 
ARN-HCV after treatment, thus the progression of liver cirrhosis and hepatocellular carcinoma be-ing stopped (8, 9). Our study results have proved 
a high efficacy of generic antiviral agents admi-nistered over 12 weeks in patients with chronic HCV, thus a sustained virologic response was re-corded over 24 weeks after treatment in 90.3% of patients undergoing Sofosbuvir + Ledipasvir and 86.4% patients receiving Sofosbuvir+Daclatasvir. 
The treatment was effective in both naî�ve patients and those who underwent a previous unsuccess-ful treatment with PEG-INF, RBV, Boceprevir or Telaprevir.
CONCLUSIONS
1. The generic direct-acting antiviral agents showed a high efficacy, having a sustained virologic respon-se in approximately 90% of patients treated with both treatment schemes.
2. The sustained virologic response was similar in both naî�ve patients and in those who underwent a previous unsuccessful antiviral treatment.3. Generic antiviral agents have been well tolerated by most patients, whereas minor side effects did not require treatment discontinuation.
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